Abstract
Ovarian cancer is the ninth most common cancer amongst women and ranked as fifth in terms of the cause of cancer related mortality accounting for more deaths than any other cancer of the female reproductive system. Gemcitabine is the most common chemotherapeutic agent used in the treatment of ovarian cancer despite of its disadvantage of having a very lesser half life. In this study, we have envisaged the use of a highly porous, biomimetic and implantable pectin scaffold embedded with gemcitabine loaded fibrin nanoconstructs to improve the half life of the drug, thereby providing localized therapy for ovarian cancer. The controlled and sustained release of the chemokine from the scaffold system was extensively analyzed in vitro different pH environments. The composite scaffolds were found to be highly biocompatible when tested with mammalian cell lines. The excellent cytotoxicity and apoptosis responses induced in ovarian cancer, PA- 1 cell lines proved that the nanocomposite Pectin scaffolds loaded with specific chemokine can be used as implantable “therapeutic wafers” for distracting metastatic cancer cells and thus improve the survival rate of ovarian cancer afflicted individuals.
Keywords: Pectin scaffolds, Fibrin nanoconstructs, Gemcitabine, Drug delivery, Ovarian cancer.
Current Drug Delivery
Title:Potential Use of Drug Loaded Nano Composite Pectin Scaffolds for the Treatment of Ovarian Cancer
Volume: 10 Issue: 3
Author(s): Sarika Chandran, G. Praveen, K.S. Snima, Shantikumar V. Nair, K. Pavithran, Krishnaprasad Chennazhi and Vinoth-Kumar Lakshmanan
Affiliation:
Keywords: Pectin scaffolds, Fibrin nanoconstructs, Gemcitabine, Drug delivery, Ovarian cancer.
Abstract: Ovarian cancer is the ninth most common cancer amongst women and ranked as fifth in terms of the cause of cancer related mortality accounting for more deaths than any other cancer of the female reproductive system. Gemcitabine is the most common chemotherapeutic agent used in the treatment of ovarian cancer despite of its disadvantage of having a very lesser half life. In this study, we have envisaged the use of a highly porous, biomimetic and implantable pectin scaffold embedded with gemcitabine loaded fibrin nanoconstructs to improve the half life of the drug, thereby providing localized therapy for ovarian cancer. The controlled and sustained release of the chemokine from the scaffold system was extensively analyzed in vitro different pH environments. The composite scaffolds were found to be highly biocompatible when tested with mammalian cell lines. The excellent cytotoxicity and apoptosis responses induced in ovarian cancer, PA- 1 cell lines proved that the nanocomposite Pectin scaffolds loaded with specific chemokine can be used as implantable “therapeutic wafers” for distracting metastatic cancer cells and thus improve the survival rate of ovarian cancer afflicted individuals.
Export Options
About this article
Cite this article as:
Chandran Sarika, Praveen G., Snima K.S., Nair Shantikumar V., Pavithran K., Chennazhi Krishnaprasad and Lakshmanan Vinoth-Kumar, Potential Use of Drug Loaded Nano Composite Pectin Scaffolds for the Treatment of Ovarian Cancer, Current Drug Delivery 2013; 10 (3) . https://dx.doi.org/10.2174/1567201811310030009
DOI https://dx.doi.org/10.2174/1567201811310030009 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology BRCA-FA Pathway as a Target for Anti-Tumor Drugs
Anti-Cancer Agents in Medicinal Chemistry The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
Mini-Reviews in Medicinal Chemistry Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry Utilization of Tumor Markers in Adnexal Masses: A Review of Current Literature
Current Women`s Health Reviews Modulation of Aquaporins by Dietary Patterns and Plant Bioactive Compounds
Current Medicinal Chemistry Synthesis, <i>In Vitro</i> Evaluation, Molecular Docking and DFT Studies of Some Phenyl Isothiocyanates as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry The Integral Nuclear Membrane Protein Nurim Plays a Role in the Suppression of Apoptosis
Current Molecular Medicine Advances in Nano Drugs for Cancer Chemotherapy
Current Cancer Drug Targets MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Exome Sequencing of Ovarian Cancer Patients to Identify Variants Predictive of Sensitivity to Platinum-based Chemotherapy
Current Pharmacogenomics and Personalized Medicine Metallothioneins and Cancer
Current Protein & Peptide Science Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy
Current Pharmaceutical Design Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
Recent Patents on Anti-Cancer Drug Discovery Current Developments in the Analysis of Proteomic Data: Artificial Neural Network Data Mining Techniques for the Identification of Proteomic Biomarkers Related to Breast Cancer
Current Proteomics